Adjunctive treatment of decompression illness with a non-steroidal anti-inflammatory drug (Tenoxicam) reduces compression requirement

Undersea and Hyperbaric Medicine

Volumn 30, Issue 3, 2003, Pages 195-205

  Bennett, M ^a   Mitchell, S ^a   Dominguez, A ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

Author keywords

Decompression illness; Non steroidal; Tenoxicam

Indexed keywords

DRUG DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; TENOXICAM;

ADJUVANT CHEMOTHERAPY; ADULT; ALGORITHM; ARTICLE; BAROTRAUMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECOMPRESSION SICKNESS; DOUBLE BLIND PROCEDURE; EAR DISEASE; FEMALE; HUMAN; HYPERBARIC OXYGEN; MALE; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; STATISTICS; TREATMENT OUTCOME;

ADULT; ALGORITHMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BAROTRAUMA; CHEMOTHERAPY, ADJUVANT; DECOMPRESSION SICKNESS; DOUBLE-BLIND METHOD; EAR DISEASES; FEMALE; HUMANS; HYPERBARIC OXYGENATION; MALE; PIROXICAM; STATISTICS; TREATMENT OUTCOME;

EID: 0642339754     PISSN: 10662936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. th ed). Saunders, London 2002: 530-556.
2. Francis TJR, Griffin JL, Momer LD, Pezeshkpour GH, Dutka AJ. Bubble induced dysfunction in acute spinal cord decompression sickness. J Appl Physiol 1990;68:1368-75.
3. Helps SC, Parsons DW, Reilly PL, Gorman DF. The effect of gas emboli on rabbit cerebral blood flow. Stroke 1990;21:94-9.
4. Helps SC, Gorman DF. Air embolism of the brain in rabbits pretreated with mechlorethamine. Stroke 1991;22:351-4.
5. Philp RB, Inwood MJ, Warren BA. Interactions between gas bubbles and components of the blood: Implications in decompression sickness. Aerospace Med 1972;43:946-56.
6. Ward CA, Koheil A, McCulloch D, Johnson WR, Fraser WD. Activation of complement at the plasma-air or serum-air interface in rabbits. J Appl Physiol 1986;60:1651-8.
7. Ogston D & Bennett B. Surface mediated reactions in the formation of thrombin, plasmin, and kallikrein. Br Med Bull 1978;34:107-12.
8. Richardson K, Mitchell SJ, Davis MF, Richards M. Decompression illness in New Zealand Divers: the 1996 experience. SPUMS J 1998;28:50-55.
9. th ed). London: WB Saunders, 1993:506-41.
10. Bennett MH. The retrieval of diving injuries in New South Wales. SPUMS J 1995;25:142-147.
11. Gardner M, Forbes C, Mitchell SJ. One hundred cases of decompression illness treated in New Zealand during 1995. SPUMS J 1996;26:222-226.
12. Bennett PB, Moon RE (eds). Diving Accident Management. Bethesda 1990, Undersea and Hyperbaric Medical Society: pp366-9.
13. Moon RE. The natural progression of decompression illness and development of recompression procedures. SPUMS J 2000;30:36-45.
14. Kizer KW. Corticosteroids in treatment of serious decompression sickness. Ann Emerg Med 1981;10:485-8.
15. Bove AA. The basis for drug therapy in decompression sickness. Undersea Biomed Res 1982;9:91-112.
16. Reeves E, Workman RD. Use of heparin for the therapeutic / prophylactic treatment of decompression sickness. Aerospace Med 1971;42:20-3.
17. Evans DE, Kobrine AI, LeGrys DC, Bradley ME. Protective effect of lidocaine in acute cerebral ischaemia induced by air embolism. J Neurosurg 1984;60:257-63.
18. Mitchell SJ. Lidocaine in the treatment of decompression illness: a review of the literature Undersea Hyperbaric Med 2001;28:165-74.
19. Douglas JD. Intramuscular diclofenac sodium as adjuvant therapy for type 1 decompression sickness: a case report. Undersea Biomed Res 1986;13:457-60.
20. Hallenback JM, Leitch DR, Dutka AJ, Greenbaum LJ, McKee AE. Prostaglandin I2, indomethacin and heparin promote postischemic neuronal recovery in dogs. Ann Neurol 1982;12:145-56.
21. Hills BA. Intermittent flow in tendon capillary bundles. J Appl Physiol 1979;46:696-702.
22. Strauss MB, Borer RC. Diving medicine: contemporary topics and their controversies. Am J Emerg Med 2001;19:232-8.
23. Nims LF. A physical theory of decompression sickness. In Fulton JF (ed) Decompression Sickness. Philadelphia 1951, WB Saunders: pp 192-222.
24. Rang HP, Dale MM, Ritter JM. Pharmacology. Edinburgh 1999, Churchill Livingstone: pp 213-7.
25. Cashman J, McAnulty G. Nonsteriodal anti-inflammatory drugs in perisurgical pain management. Mechanisms of action and rationale for optimum use. Drugs 1995;49:51-70.
26. Bond JG, Moon RE, Morris DL. Initial table treatment of decompression sickness and arterial gas embolism. Aviat Space Environ Med 1990;61:738-43.
27. Lipsky PE, Brooks P, Clifford LJ et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Archives of Internal Medicine 2000;160:913-920.
28. Todd PA, Clissold SP. Tenoxicam: an update of its pharmacology and therapeutic efficacy in rheumatic disease. Drugs 1991;41:625-646.
29. Jones RDM, Endre Z, Miles W, Frankerd R, Chilvers M, Wilgoss D. Tenoxicam IV for major gynaecological surgery - effects on renal function. Anaesthesia and Intensive Care 2000;28:501-509.
30. Nilson OG. Clinical pharmacokinetics of tenoxicam. Clinical Pharmacokinetics 1994;26:16-43.
31. Lee VC, Rowlingson JC. Pre-emptive analgesia: update on nonsteroidal anti-inflammatory drugs in anaesthesia. In: Lake CL, Rice LJ, Sperry RJ (eds). Advances in Anaesthesia, New York, Mosby Year Book Inc 1995;12:69-110.